Capricor Therapeutics Stock Plummets 68% After FDA Documents Raise Drug Concerns

Capricor Therapeutics (NASDAQ: CAPR) shares plummeted 67.7% in a single day, erasing more than $190 million in market capitalization after U.S. Food and Drug Administration documents raised significant concerns about the company's lead drug candidate.

FDA Documents Trigger Sell-Off

The immediate catalyst for the collapse on July 27, 2026, was the release of FDA briefing documents concerning deramiocel, Capricor's investigational therapy for Duchenne muscular dystrophy. According to Investing.com, the documents' tone and lingering uncertainties shattered investor optimism that had been building around the drug's potential approval, leading to the massive sell-off.

Fundamental Warning Signs

The dramatic stock decline was preceded by clear signs of financial distress, despite bullish analyst calls and a cash runway projected into 2027. The company's business model was almost entirely dependent on a single asset without a sustainable revenue stream.

Key red flags included:

Ad

• Zero Revenue: Capricor reported $0 in revenue for the first quarter of 2025 and the fourth quarter of 2025, down from $4.9 million and $11.1 million in the respective prior-year periods.
• Widening Losses: The company's net loss more than doubled, growing from $40.5 million in 2024 to $105 million in 2025, with negative earnings per share each quarter.
• Insider Selling: The company's General Counsel sold over $732,000 in shares near the stock's peak, weeks before the collapse.

Disconnect in Market Sentiment

These fundamental weaknesses stood in stark contrast to the optimistic sentiment from many market analysts, who had maintained "Buy" ratings with price targets as high as $60 per share. The sell-off brings the stock price closer to its all-time low of $0.88, set in March 2020.

Capricor's situation underscores the high-stakes risk inherent in clinical-stage biotechnology firms. With its valuation almost entirely tethered to the success of a single drug candidate, any regulatory setback was poised to have an outsized impact on its share price.